Kimberly L Blackwell, MD
Kimberly L Blackwell, MD, is Professor of Medicine and Assistant Professor of Radiation Oncology at Duke University Medical Center. She also serves as the Co-Director of the Duke Cancer Institute’s Women’s Cancer Program, Associate Director for Strategic Relations at the Duke Cancer Institute, Global Research Scholar for the Susan G. Komen for the Cure, and Senior Strategist for the Duke Innovation and Entrepreneurship Program. Her clinical and research interests include various topics in breast cancer including antibody drug conjugates, novel HER2 therapies, breast cancer vaccines, and other experimental therapeutics. She has studied and served as the PI on studies that led to approval of four approved agents- lapatinib (2009), T-DM1 (2012), and two G-CSF biosimilars (2015). Because of her work, she has received numerous awards including being named one of TIME magazine’s 100 most influential people in the world in 2013.